09th week of 2018 patent applcation highlights part 10 |
Patent application number | Title | Published |
20180055852 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2018-03-01 |
20180055853 | METHOD OF TREATMENT OF AGGRESSION - The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity. | 2018-03-01 |
20180055854 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 2018-03-01 |
20180055855 | PROGESTERONE FORMULATIONS HAVING A DESIRABLE PK PROFILE - This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount. | 2018-03-01 |
20180055856 | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM - Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D | 2018-03-01 |
20180055857 | TREATMENT OF ACNE VULGARIS WITH SEQUENTIAL TOPICAL FORMULATIONS COMPRISING ANTIMICROBIAL ORGANIC ACID ANIONS IN ALKALINE PHASE - A method for treating skin conditions of a patient, including acne vulgaris, includes the steps of formulating an acidic aqueous solution having no less than a 0.1% concentration of mandelic acid and up to and including a 2.0% concentration of salicylic acid, formulating an alkaline aqueous solution having an alkaline nitrite salt as a first alkaline salt and a second alkaline salt of an acid selected from the anion of chlorous acid, fumaric acid, mandelic acid and a combination thereof. Thereafter, sequentially applying the acidic aqueous solution directly to the afflicted portion of the skin of the patient and, at least five minutes later, but no more than ten minutes later, applying the alkaline aqueous solution to that portion of the patient to which the acidic aqueous solution has already been applied. | 2018-03-01 |
20180055859 | 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF - Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days. | 2018-03-01 |
20180055860 | Method of Treating Acute Coronary Syndromes - The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction. | 2018-03-01 |
20180055861 | STABLE READY TO USE CYCLOPHOSPHAMIDE LIQUID FORMULATIONS - The present invention relates to stable ready to use liquid formulations of Cyclophosphamide for parenteral use. The ready to use composition comprises Cyclophosphamide dissolved in a solvent system comprising a solvent, cosolvent(s) and antioxidant(s). | 2018-03-01 |
20180055862 | COMPOSITIONS FOR ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING LOW BACK PAIN - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as low back pain. | 2018-03-01 |
20180055863 | METHODS OF PRODUCING SIALOOLIGOSACCHARIDES AND USES THEREOF - The present invention provides a method of producing a sialooligosaccharide, which comprises: (1) hydrolyzing a sialoglycoprotein by heating at a temperature from 70 to 90° C. in an alkaline aqueous solution; and (2) purifying the hydrolysate to obtain the sialooligosaccharide, wherein a weight ratio of sialic acid to hexose contained in the resulting sialooligosaccharide is from 0.5 to 0.9. | 2018-03-01 |
20180055864 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF - Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases. | 2018-03-01 |
20180055865 | Methods of Treatment - The present disclosure provides a biochemical basis of nephrotic syndrome and provides and explanation for the observed proteinuria and other effects. As a result, the present disclosure provides method for treating and/or preventing nephrotic syndrome as well as methods of alleviating symptoms associated with nephrotic syndrome. The present disclosure further provides methods for reducing proteinuria in nephrotic syndrome and other disease states as discussed herein. | 2018-03-01 |
20180055866 | Control Release of Fat Soluble Antioxidants from an Oral Formulation and Method - Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the first layer is a second layer comprising a mixture of a flavonoid and polysaccharide or polypeptide binder or polymer gel. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer. The fourth and third layers dissolve in a low pH environment and release the fat soluble antioxidant and ions in the seed granule fissures. | 2018-03-01 |
20180055867 | METHODS FOR THE TREATMENT AND PROPHYLAXIS OF HIV AND AIDS - The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I | 2018-03-01 |
20180055868 | METHODS AND COMPOSITIONS FOR STIMULATING BONE REGENERATION - The invention provides methods and compositions for stimulating or promoting bone regeneration or repairing bone fracture or for stimulating or increasing differentiation or activation of osteoblasts by administering to a subject a therapeutically effective amount of an adenosine receptor agonist, or an analog, derivative or combination thereof, an adenosine receptor antagonist, or an analog, derivative or combination thereof, or adenosine or a compound that upregulates, increases the amount of or increases the biological activity of adenosine. The invention also extends to pharmaceutical compositions such as those comprising an agent that modulates an adenosine receptor such as an adenosine A | 2018-03-01 |
20180055869 | COMPOSITIONS AND METHODS FOR MODULATING RNA - Aspects of the invention relate to methods for increasing gene expression in a targeted manner. In some embodiments, methods are provided for increasing expression of a gene expressed in a liver cell. In some embodiments, methods and compositions are provided that are useful for posttranscriptionally altering protein and/or RNA levels in a targeted manner. Aspects of the invention disclosed herein provide methods and compositions that are useful for protecting RNAs from degradation (e.g., exonuclease mediated degradation). | 2018-03-01 |
20180055870 | VISCOSE-AMINO BODILY FLUIDS CONTRA - The abstract of the disclosure is to give clear understanding of what Viscose-Amino Bodily Fluid CONTRA is and how it is a very readily available ingredient in manufacturing products and an ingredient on Pharmaceuticals and how it replaces the hard-to-find Human Tissue donations which was almost extincting a majority of products on the market today for non availability of supplies. | 2018-03-01 |
20180055871 | Nutritional composition or pharmaceutical and dietary supplement containing said nutritional or pharmaceutical composition - The present invention relates to a nutritional or pharmaceutical composition for the treatment or prevention of gastroesophageal reflux disease comprising at least one salt of alginic acid and a salt of hyaluronic acid. The nutritional or pharmaceutical composition according to the invention has the advantage of being able to be used for the treatment or prevention of gastroesophageal reflux disease by acting, through the formation of a spongy gel, as a protective barrier that mechanically protects the walls of the gastroesophageal mucosa from possible erosion by acid in the contents of the stomach. According to the invention, a dietary supplement that comprises said nutritional or pharmaceutical composition for the treatment or prevention of gastroesophageal reflux disease is also provided. | 2018-03-01 |
20180055872 | Composition Comprising Neoagarooligosaccharide As Active Ingredient, For Prevention or Treatment of Sepsis or Septic Shock - The present invention relates to a composition for prevention or treatment of sepsis or septic shock, in which the composition includes neoagarooligosaccharide as an active ingredient, and the neoagarooligosaccharide according to the present invention has an excellent effect in terms of immune enhancement by effectively suppressing inflammation, and also exhibits a good effect in preventing sepsis, and therefore can be effectively used in pharmaceuticals and functional foods for prevention or treatment of sepsis or septic shock and immune enhancement. | 2018-03-01 |
20180055873 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION - A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these. | 2018-03-01 |
20180055874 | FAST ACTING JOINT RELIEF FORMULATIONS - The instant invention provides a method and composition for treating or preventing osteoarthritis, joint effusion, joint inflammation and pain, synovitis, lameness, post operative arthroscopic surgery, deterioration of proper joint function including joint mobility, the reduction or inhibition of metabolic activity of chondrocytes, the activity of enzymes that degrade cartilage, said method comprising administering effective amounts of | 2018-03-01 |
20180055875 | Polyethylene Glycol Compositions for Controlling Relapse of Herpes Labialis, Herpes Genitalis, and Herpes Zoster - The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG. | 2018-03-01 |
20180055876 | PREVENTION OF PREGNANCY COMPLICATIONS BY NOBLE GAS ADMINISTRATION - Disclosed are means of preventing, reducing and/or treating pregnancy associated complications by administration of Noble Gas mixtures, directly by inhalation, or by other means of direct or indirect introduction, with the intended effect of reducing immunological/inflammatory events associated with said complications. In one embodiment the invention teaches the modulation of the maternal-fetal unit from a Th1/Th17 predisposition towards a Th2/Treg environment by inhalation of a combination of 30% xenon gas admixed with air, or combinations of medical grade oxygen and nitrogen. | 2018-03-01 |
20180055877 | THERAPEUTIC NANOPARTICLES AND METHODS THEREOF - Described herein is a method of preparing a hybrid hydrogel paramagnetic nanoparticle. In certain embodiments, the hybrid hydrogel paramagnetic nanoparticle comprises a therapeutic agent. In certain embodiments, the nanoparticle contains alcohol. In certain embodiments, the nanoparticles incorporate fatty acids. Also described herein, is a method of preparing a hybrid hydrogel NO-releasing nanoparticle. In another embodiment, provided herein is a method of preparing a S-nitrosocaptopril hydrogel nano-particle. Also described herein is a method of preparing a curcumin-based hydrogel nanoparticle. Further, described herein is a method for treating a bacterial infection in a burn wound using curcumin-based hydrogel nanoparticles. Also provided herein is a method of treating a fungal infection using photoactivated curcumin-based hydrogel nanoparticles. In certain embodiments, the fungal infection is caused by dermatophytic fungi. | 2018-03-01 |
20180055878 | TOPICAL ARTHRITIS TREATMENT DEVICE - The present disclosure relates to a method of forming a topical treatment device for arthritis. The method can include determining an arthritis treatment surface area of a user, forming a flexible metal substrate conforming to the arthritis treatment surface area, and forming a gold composition on the flexible metal substrate. | 2018-03-01 |
20180055879 | Pharmaceutical Composition for Improving Health, Cure Abnormalities and Degenerative Disease, Achieve Anti-aging Effect of Therapy and Therapeutic Effect on Mammals and Method Thereof - A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals. | 2018-03-01 |
20180055880 | COMPOSITION AND METHOD FOR ALLERGEN DEACTIVATION - The present disclosure provides compositions and methods useful in the deactivation of allergens. The compositions can comprise a peroxide and can particularly be at a relatively low pH (e.g., less than 5). The compositions exhibit efficacy for deactivation of a wide variety of allergens and are suitable for application to one or more types of surfaces to provide for deactivation of at least a portion of allergens present on the surface. | 2018-03-01 |
20180055881 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 2018-03-01 |
20180055882 | FUNCTIONAL IMMUNOPHENOTYPING OF LEUKOCYTES IN HUMAN TISSUES - Methods of detecting surface markers on T-cells from skin samples are provided. T-cells can be isolated from skin samples for example using single density centrifugation. The percentage of CD8 | 2018-03-01 |
20180055883 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2018-03-01 |
20180055884 | CELL SUSPENSION FOR USE IN THE TREATMENT OF LOWER EXTREMITY PERIPHERAL ARTERY DISEASE - The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising:
| 2018-03-01 |
20180055885 | BIOACTIVE RENAL CELLS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE - The present invention concerns methods of using bioactive renal cell populations to provide regenerative effects to a native kidney for the treatment of chronic kidney disease. | 2018-03-01 |
20180055886 | METHOD FOR COLLECTING FUNCTIONAL CELLS IN VIVO WITH HIGH EFFICIENCY - Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body. | 2018-03-01 |
20180055887 | METHOD FOR PREPARING INDUCED MESENCHYMAL STEM CELLS AND IMPROVING MESENCHYMAL STEM CELL'S CHARACTERS AND ITS APPLICATIONS - The present invention generally relates to a method for preparing induced mesenchymal stem cells (iMSCs) and its applications. The iMSCs, like MSCs, can differentiate into multiple lineages, which may be beneficial for disease treatments. In addition, the present invention also provides a method for improving the MSC's functional characteristics such that the MSCs are more suitable for cell therapy or in vitro applications. | 2018-03-01 |
20180055888 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS - The invention encompasses compositions and method of treating a vascular disease such as peripheral artery disease, The methods involve—administering to a patient in need thereof, an effective amount of a composition comprising a population of cells such as mesenchymal stem cells (MSCs) and a non-muscle myosin 0 antagonist such as blebbistatin. Non-muscle myosin II antagonists are disclosed to surprisingly and dramatically accelerate MSC-triggered regeneration of damaged tissues arid unexpectedly and drastically reduce severe complications of stem cell treatment. | 2018-03-01 |
20180055889 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 2018-03-01 |
20180055890 | Pancreatic Endocrine Progenitor Cell Therapies for the Treatment of Obesity and Type 2 Diabetes (T2D) - Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population. | 2018-03-01 |
20180055891 | COMPOSITIONS AND METHODS FOR REPROGRAMMING ADULT CELLS THROUGH THE STEMNESS OF A PLATELET RICH FRACTION OF BLOOD CONTAINING PLATELET-LIKE CELLS IN HUMANS - The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from functionally reprogrammed adult cells, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. | 2018-03-01 |
20180055892 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing cancer. | 2018-03-01 |
20180055893 | USE OF LACTOBACILLUS PLANTARUM COMPOSITION FOR MANUFACTURING ANTI-FATIGUE PROBIOTIC COMPOSITION FOR IMPROVE EXERCISE PERFORMANCE - The present invention is directed to a use of anti-fatigue probiotic bacteria for improving exercise performance, particularly the fatigue caused by exercise. The anti-fatigue probiotic bacteria increases muscle mass and endurance, decreases blood lactate, ammonia, and creatine kinase concentration, and changes body composition; the said bacteria can be used to improve exercise performance. | 2018-03-01 |
20180055894 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING LACTIC ACID BACTERIA-DERIVED EXTRACELLULAR VESICLES AS ACTIVE INGREDIENTS - Provided is a composition for preventing, ameliorating, or treating inflammatory diseases, the composition including, as active ingredients, lactic acid bacteria-derived extracellular vesicles isolated from culture fluid of lactic acid bacteria; and a method for diagnosing atopic dermatitis. The composition including the lactic acid bacteria-derived extracellular vesicles as active ingredients is expected to be usefully used in development of drugs, cosmetics, or health functional food for preventing, ameliorating, or treating inflammatory diseases such as atopic dermatitis, chronic rhinitis, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, sepsis, etc. Also, the composition will be usefully used for diagnosis of atopic dermatitis by measuring the distribution of lactic acid bacteria-derived extracellular vesicles in a urine or blood sample. | 2018-03-01 |
20180055895 | BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS - The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of | 2018-03-01 |
20180055896 | COMPOSITIONS AND METHODS FOR INCREASING LIFESPAN AND HEALTH SPAN - Disclosed herein are compounds, extracts, and active fractions of the plant | 2018-03-01 |
20180055897 | FUNCTIONAL FOODS AND BEVERAGES WITH SYNERGISTIC PROPERTIES TO PROMOTE HOMEOSTASIS - The present invention provides compositions having synergistic antioxidant properties in the modulation of Toll-like receptor signaling for the promotion of homeostasis, immunity, energy conservation, protection of neural cells and anti-inflammatory responses, said compositions comprising plant and/or fruit extracts and a natural sweetener with high oxidation potential as defined by ORAC value. | 2018-03-01 |
20180055898 | TRADITIONAL CHINESE MEDICINE COMPOSITION FOR PREVENTING AND TREATING EXTERNALLY DIABETES AND A METHOD OF USING THE SAME - The invention discloses a traditional Chinese medicine composition and a method thereof for preventing and treating externally diabetes, which is characterized in that the traditional Chinese medicine composition is composed of astragalus membranaceus, salvia miltiorrhiza, stigma maydis, cortex lycii radicis, wolfberry, Prunella vulgaris, mulberry leaf, cornus officinalis, lycopodium clavatum, the root of bidentate achyranthes, rhizoma chuanxiong, Chinese atractylodes, yam, puerarin, fructus arctii, cassia twig; the method of use is to put a 40-50 g/ml medicine bags of the Chinese herbal medicine powder or decoction into a foot pot, brew with boiling water, and then steam more than 10 minutes with the traditional Chinese medicine steam after stirring evenly. When the water is cooled to 40-42° C., soaking feet once a day before going to bed, a course for foot soaking being 20 days; the contents of blood glucose and symptom of polydipsia, polyuria and polyphagia of the patients can be effectively reduced and disappeared by the foot bath in traditional Chinese medicine, thus improving the immunity of the body and activating the autoimmunity as well as promoting the self-healing ability for the disease; and also such diseases as diabetic peripheral neuropathy (DPN), diabetic foot, diabetic nephropathy (DN), uremia caused by renal insufficiency resulted from diabetes can be prevented. | 2018-03-01 |
20180055899 | Compositions and Methods for Managing or Improving Bone Disorders, Cartilage Disorders, or Both - The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of useful for promoting, managing or improving bone health, cartilage health or both, or for preventing or treating a bone disorder, cartilage disorder or both. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other bone and cartilage management agents, such as calcium, magnesium, zinc, boron, vitamin D, vitamin K, glucosamine and/or chondroitin compounds, non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, neuropathic pain relief agents, or the like. | 2018-03-01 |
20180055900 | METHOD FOR PRODUCING AN EXTRACT OF A MATRIX OF VEGETABLE ORIGIN BY EXTRUSION WITH A HYDROTROPE SOLUTION - The invention relates to a method for producing an extract of a matrix of vegetable origin, particularly a plant, characterised in that the matrix of vegetable origin undergoes a mechanical treatment consisting in extruding the matrix of vegetable origin in an extruder, in association or not with a heat treatment, in the presence of an aqueous solution containing at least one hydrotrope agent, particularly at a concentration at least equal to the minimum hydrotrope concentration thereof, followed by an operation of recovering the extract. | 2018-03-01 |
20180055901 | Regulation of Brain Biogenic Amines Associated with Depression by a Formulation from Botanical Source - Provided herein are anti depressant and anxiolytic herbal formulations including: 225-450 mg of | 2018-03-01 |
20180055902 | Composition for preventing, treating and improving of voiding dysfunction comprising extract from Piper longum L. - The present invention relates to a pharmaceutical composition for preventing or treating voiding dysfunction and a health functional food for preventing or improving of voiding dysfunction, comprising extract of | 2018-03-01 |
20180055903 | HOMEOPATHIC COMPOSITION COMPRISING HYPERICUM PERFORATUM EXTRACT AND ESSENTIAL OILS FOR THE TREATMENT OF NEUROPATHIC PAIN - The present invention provides a method of treating neuropathic pain by administering a topical homeopathic composition to a mammalian subject. The homeopathic formulation contains homeopathic active ingredients comprising | 2018-03-01 |
20180055904 | EUTECTIC EXTRACTION SOLVENTS, EXTRACTION METHODS BY EUTECTIGENESIS USING SAID SOLVENTS, AND EXTRACTS DERIVED FROM SAID EXTRACTION METHODS - A eutectic extraction solvent for extracting plant (e.g. vegetable) and/or animal and/or prokaryotic biological material, wherein the solvent is a clear, stable and fluid mixture comprising: (a) betaine or a hydrated form of betaine; (b) at least one hydrogen bond donor compound selected from the group consisting of polyols and organic acids; and (c) water with the proviso that the eutectic extraction solvent does not contain any exogenous sugar and/or amine salt and/or anion. | 2018-03-01 |
20180055905 | BANANA FERMENTATION PRODUCT AND MANUFACTURING METHOD AND USE OF THE SAME - The present invention provides a banana fermentation product, which is obtained by subjecting a banana pulp juice to a pre-fermentation and then a post-fermentation, wherein the pre-fermentation is conducted in the presence of | 2018-03-01 |
20180055906 | METHOD FOR DESTROYING EXOSOMES, KIT FOR DESTROYING EXOSOMES, AND METHOD FOR ISOLATING EXOSOMES DERIVED FROM NORMAL CELLS - A method for destroying exosomes of the present invention includes a step of preparing an antimicrobial peptide; and a step of allowing the antimicrobial peptide to coexist with an exosome to destroy the exosome. | 2018-03-01 |
20180055907 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 2018-03-01 |
20180055908 | PREVENTION AND/OR TREATMENT OF HEARING LOSS OR IMPAIRMENT - The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS. | 2018-03-01 |
20180055909 | METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS - The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient. | 2018-03-01 |
20180055910 | METHOD OF PREVENTION AND INHIBITION OF PRETERM LABOR - Methods for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including administering a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof. Pharmaceutical compositions for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof. | 2018-03-01 |
20180055911 | Targeted Therapeutic Proteins - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 2018-03-01 |
20180055912 | Three Dimensional Healing Kit - Invention; is about the kit that enables three-dimensional healing with the platelet-rich fibrin framework support used in hard and soft tissue healing. | 2018-03-01 |
20180055913 | RECOMBINANT COLLAGEN IV SURROGATES AND USES THEREOF - The disclosure describes compositions that mimic certain structural and functional characteristics of collagen IV. Additionally provided are methods for the recombinant production of said compositions and particular methods of use. | 2018-03-01 |
20180055914 | STABLE PHARMACEUTICAL FORMULATION COMPRISING A RECONSTITUTED PULMONARY SURFACTANT COMPOSITION - Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders. | 2018-03-01 |
20180055915 | COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER - The invention provides novel therapeutically methods and pharmaceutical compositions for treating prostate cancer with increased survival rate and improved treatment outcome. Methods and compositions of the invention can be used to prevent, delay, reduce and/or drug resistance and to increase, restore and/or prolong the effective treatment of prostate cancer with anti-androgen compounds. | 2018-03-01 |
20180055916 | DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B. | 2018-03-01 |
20180055917 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES - The invention provides compositions and methods for treating inflammatory diseases, such as cardiac or hepatic inflammatory diseases, involving the use of parasite-derived neurotrophic factor (PDNF), or fragment of PDNF. | 2018-03-01 |
20180055918 | Clostridium Histolyticum Enzymes and Methods for the Use Thereof - The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration. | 2018-03-01 |
20180055919 | ANTIGEN SPECIFIC TREGS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Antigen specific regulatory T cells are described and related compositions, methods and systems. Methods to generate an antigen specific anti-inflammatory regulatory T cell is provided, the method comprising contacting either a T cell or an antigen presenting cell with a zwitterionic polysaccharide conjugated to the antigen for a time and under condition to generate an antigen specific regulatory T cell that is capable of inhibiting a pro-inflammatory response against the antigen. | 2018-03-01 |
20180055920 | VACCINE, THERAPEUTIC COMPOSITION AND METHODS FOR TREATING OR INHIBITING CANCER - The present invention provides a method of preparing an anti-cancer composition comprising activated immune cells and a pharmaceutically acceptable excipient. The present invention further provides a method of contacting immune cells obtained from an animal with an optimal combination of activating agents and with an immunogenic material to form the activated immune cells. | 2018-03-01 |
20180055921 | MATERIALS AND METHODS FOR PRODUCING IMPROVED LENTIVIRAL VECTOR PARTICLES - Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. | 2018-03-01 |
20180055922 | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS - The present invention related to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. Specifically, the invention provides a method of identifying tumor specific neoantigens that alone or in combination with other tumor-associated peptides serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor responses. | 2018-03-01 |
20180055923 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF Ebp PILUS-RELATED DISEASES - The present invention relates to compositions comprising EbpA and methods of use thereof. Specifically, methods useful in the treatment and prevention of EbpA-associated infections. | 2018-03-01 |
20180055924 | METHODS AND COMPOSITIONS FOR STABILIZING DRIED BIOLOGICAL MATERIALS - The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines. | 2018-03-01 |
20180055925 | DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS - A particle construct is disclosed that includes a synthetic core with a solid surface coated with a lipid bilayer, SpoVM adhered to the lipid bilayer; and SpoIVA adsorbed to the SpoVM. In additional embodiments, an agent of interest can be covalently linked to the SpoIVA. In specific, non-limiting examples, the agent of interest is an enzyme, a detectable marker, a pharmaceutical compound, an immunosuppressant or a vaccine. Methods of using the particle constructs are disclosed, such as for treating infections, treating a tumor, delivering a vaccine, treating an autoimmune disorder or ameliorating an allergic reaction. Method are also disclosed for degrading an environmental pollutant. Methods are also disclosed for producing these particle constructs. | 2018-03-01 |
20180055926 | Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer - A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene. | 2018-03-01 |
20180055927 | METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES - The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane. | 2018-03-01 |
20180055928 | Tumor specific oligosaccharide epitopes and use thereof - The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer. | 2018-03-01 |
20180055929 | Stable Aqueous Formulations of Adalimumab - The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2018-03-01 |
20180055930 | Stable Aqueous Formulations of Adalimumab - The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same. | 2018-03-01 |
20180055931 | ANIMAL CELL REGENERATION SPEED CONTROLLING METHOD AND ANIMAL CELL REGENERATION SPEED CONTROLLER - The present invention is a method for controlling a regeneration speed of an animal cell that includes a step of grasping tide-generating force and a step of giving a physical or chemical stimulus to the animal cell according to the magnitude of variation in the tide-generating force. | 2018-03-01 |
20180055932 | STERILISATION OF S-NITROSOTHIOLS - This invention provides a method of sterilising an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use. | 2018-03-01 |
20180055933 | BIOCERAMIC COMPOSITIONS AND BIOMODULATORY USES THEREOF - The subject matter described herein is directed to articles, compositions, systems, and methods of using and preparing bioceramic compositions and to the bioceramic compositions. A bioceramic composition of the disclosure radiates infrared energy or rays and can be used in the treatment of various conditions. | 2018-03-01 |
20180055934 | FORMULATION FOR PHOTODYNAMIC THERAPY - Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide. | 2018-03-01 |
20180055935 | METHOD FOR THE PRODUCTION OF A FORMULATION OF A HYPERICIN SALT - Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide. | 2018-03-01 |
20180055936 | Acetylcysteine Compositions and Methods of use Thereof - A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed. | 2018-03-01 |
20180055937 | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH MULTIPLE SCLEROSIS - Compositions and methods for treating one or more symptoms one or more symptoms such as reduced sexual desire and fecal compaction are provided. Accordingly, the disclosed composition can be administered to subjects in need thereof, including patients with multiple sclerosis, particularly in patients in which multiple sclerosis symptoms are exacerbated in the premenstrual time period/during the menstrual period. | 2018-03-01 |
20180055938 | Medication With Improved Taste And Sensory Experience - A liquid medication in a bottle that comprises three to four pharmaceutical actives selected from the group consisting of guaifenesin, acetaminophen, dextromethorphan, phenylephrine, pharmaceutically acceptable salts thereof and combinations thereof, ethyl 3-(p-menthane-3-carboxamido)acetate and menthol. The liquid medication can provide a taste and sensory experience that appeals to consumers. | 2018-03-01 |
20180055939 | EXCIPIENTS FOR USE IN ADENO-ASSOCIATED VIRUS PHARMACEUTICAL FORMULATIONS AND PHARMACEUTICAL FORMULATIONS MADE THEREWITH - Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions. | 2018-03-01 |
20180055940 | ANTIBODY AND PROTEIN FORMULATIONS - Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations. | 2018-03-01 |
20180055941 | INJECTABLE PREPARATION - An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s | 2018-03-01 |
20180055942 | Ionically Crosslinked Polyelectrolytes as Underwater Adhesives and Controlled Release Vehicles - Underwater adhesive materials, methods of making the same, and methods of using the same are described. | 2018-03-01 |
20180055943 | OPHTHALMIC LUBRICATING SPRAY - An ophthalmic composition for administration as a spray to the eye is provided. The ophthalmic composition comprises a lubricant comprising hydroxypropyl methylcellulose (HPMC), mineral oil, and sterile water. The ophthalmic composition is also configured as a delivery vehicle for administration of ophthalmic pharmaceuticals to the eye. A method of treating keratoconjunctivitis sicca by administering the ophthalmic composition is also provided. | 2018-03-01 |
20180055944 | NOVEL ANTIBODY-ALBUMIN-DRUG CONJUGATES (AADC) AND METHODS FOR USING THEM - The present invention relates to compositions and methods using an isolated chimeric molecule, wherein the isolated chimeric molecule comprises an antibody, one or more albumin motifs, optional peptide linkers, and two or more antibiotics or cytotoxic drug molecules conjugated to the unpaired cysteine residues, optionally through linkers. In one embodiment, each of the said albumin motifs in the isolated chimeric molecule contains 2 or more unpaired cysteine residues. In another embodiment, the said antibody in the isolated chimeric molecule targets antigens on cancer cells or drug-resistant bacteria. In another embodiment, the cancer cells have upregulated macropinocytosis. In another embodiment, the cancer cells contain one or more mutations in their RAS family genes. The compositions of the invention are used to treat drug-resistant bacterial infections and cancers, preferably the ones with upregulated macropinocytosis, and the ones containing one or more mutations in their RAS family genes. | 2018-03-01 |
20180055945 | METHOD OF DEVELOPING A VACCINE USING PEPTIDE-POLY IC COMPLEXES - The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer and their administration to a subject in order to elicit a T cell response in the subject. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified so they can spontaneously form complexes with a synthetic nucleic acid, such as Poly IC, that functions as an immunological adjuvant. The peptide-nucleic acid complexes are dramatically more immunogenic as compared to the separate components. The procedure for developing the vaccine involves the conjugation of a synthetic peptide containing a C residue to poly-K using a bi-functional cross-linking reagent (SMCC). The peptide/poly-K complex was then formulated with CMC and poly-IC to produce a self-adjuvant vaccine that was 36-fold more effective as compared to the same peptide administered mixed with the same adjuvant (but not complexed to it). | 2018-03-01 |
20180055946 | VERSATILE PEPTIDE-BASED MULTI-ARM LINKERS FOR CONSTRUCTING PHARMACEUTICAL MOLECULES - Disclosed herein are linker units comprising a center core, a plurality of linking arms, and optionally, a coupling arm. According to the embodiments of the present disclosure, the present linker units further comprises a targeting element and an effector element. Also disclosed herein are methods for treating various diseases using such linker units. | 2018-03-01 |
20180055947 | METHOD FOR REMOVING WEAKLY BOUND FUNCTIONAL MOIETIES FROM CELL TARGETING CONJUGATES - This disclosure describes a method for preparing stable cell targeting conjugates. A further aspect of this disclosure relates to the stable cell targeting conjugates obtainable by the method and to pharmaceutical compositions comprising these stable cell targeting conjugates. A last aspect of this disclosure relates to the use of these conjugates and pharmaceutical compositions as a medicament. | 2018-03-01 |
20180055948 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same - The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC). | 2018-03-01 |
20180055949 | CANCER THERAPEUTICS - Disclosed herein are methods of treating pancreatic cancer and/or multiple myeloma cancer in a subject, comprising: providing a composition comprising a micelle construct attached to curcumin; and treating pancreatic cancer and/or multiple myeloma cancer in the subject by administering a therapeutically effective dosage of the composition to the subject. Further disclosed herein are pharmaceutical compositions, comprising: an inhibitor of NF-kB; a glut-1 antibody; and a pharmaceutically acceptable carrier. Also disclosed herein are methods of using the same. | 2018-03-01 |
20180055950 | NEURONAL SPECIFIC TARGETING OF CAVEOLIN EXPRESSION TO RESTORE SYNAPTIC SIGNALING AND IMPROVE COGNITIVE FUNCTION IN THE NEURODEGENERATIVE BRAIN AND MOTOR FUNCTION IN SPINAL CORD - The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding Caveolin-1. | 2018-03-01 |
20180055951 | ENDONUCLEASE TARGETING BLOOD COAGULATION FACTOR VIII GENE AND COMPOSITION FOR TREATING HEMOPHILIA COMPRISING SAME - The present invention provides a method for inducing an inversion of normal blood coagulation factor VIII (F8) gene, a method for correcting an inversion of blood coagulation factor VIII gene in which the inversion has occurred, and a Hemophilia A patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present invention effectively reproduces the inversion of intron 1 and intron 22 of the F8 gene, which is responsible for the majority of severe hemophilia A, and thereby may be effectively used for studying the development mechanism of hemophilia A and as a research tool for screening therapeutic agents. The inversion-corrected induced pluripotent stem cell constructed according the method of the present invention enables an efficient and fundamental treatment for hemophilia A by restoring a genotype in which mutation has occurred to a wild type-like state, without limitation via normal gene or protein delivery. | 2018-03-01 |
20180055952 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PROTEIN - The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method. | 2018-03-01 |